Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Autogenomics

Autogenomics

Dec 12, 2019

Prescient Medicine, Erasmus MC Partner to Study Opioid Addiction Risk Test

Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway.

Apr 23, 2019

Prescient Medicine Acquires AutoGenomics

Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.

Jun 06, 2018

FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

Aug 29, 2017

Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics

Premium

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

Sep 09, 2016

WuXi to Distribute AutoGenomics' MDx System in China

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

Jul 24, 2015

AutoGenomics to Withdraw Planned IPO; Eyes Launch of New MDx Platform in Q1 2016

Premium

The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said. 

Feb 04, 2015

AutoGenomics Sets Price Range for Planned IPO, Anticipates up to $46.6M in Proceeds

The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.

Oct 08, 2014

AutoGenomics Seeks to Raise $60M in IPO

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

Jul 09, 2014

Genomas, Autogenomics Codeveloping Multiplex Genetic Test for Statin Efficacy and Adverse Events

Premium

Originally published July 8.

Jul 07, 2014

Genomas, AutoGenomics Partner to Advance Dx to Personalize Statin Treatments

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Pages

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.